$129.4 Million

Immuneering Corporation

Initial Public Offering

Bookrunner, July 2021

Immuneering Corporation (the “Company”) is a preclinical biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its knowledge of translational bioinformatics to every stage of the drug development process. The Company’s lead oncology product candidate, IMM-1-104, is designed to be a potent and highly selective dual-MEK inhibitor that further disrupts KSR in RAS-mutant advanced solid tumors. Apart from oncology, Immuneering is also developing a preclinical pipeline of neuroscience programs with an initial focus on Alzheimer’s Disease, or AD.

More Like This

Mar 2022
$79.4 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Nov 2021
$116.3 Million

Initial Public Offering

Bookrunner

View Details
Nov 2021
$500.3 Million

Initial Public Offering

Bookrunner

View Details